Corpus ID: 43659108

Biologic Disease-Modifying Antirheumatic Drugs

@inproceedings{Burke2014BiologicDA,
  title={Biologic Disease-Modifying Antirheumatic Drugs},
  author={Rachel A. Burke and N. White},
  year={2014}
}
1. Distinguish between biologic DMARD use and nonbiologic DMARD use in the treatment of rheumatoid arthritis (RA). 2. Assess the differences between classes of biologic disease-modifying antirheumatic drug (DMARD) therapy. 3. Based on individual patient characteristics, construct a treatment and monitoring plan for a patient with RA and, when appropriate, include biologic DMARD therapy. 4. Justify switching agents or usingcombination therapy with nonbiologic DMARDs when treatment with DMARD… Expand
5 Citations

Figures and Tables from this paper

References

SHOWING 1-10 OF 76 REFERENCES
Assessing the safety of biologic agents in patients with rheumatoid arthritis.
  • 135
  • PDF
Aspects of TNF inhibitor therapy in rheumatoid arthritis
  • 18
  • PDF
Anakinra for rheumatoid arthritis.
  • 158
Rheumatoid arthritis and cardiovascular disease: an update on treatment issues
  • 35
  • PDF
...
1
2
3
4
5
...